Current Report Filing (8-k)
June 04 2018 - 4:34PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
May 29, 2018
BIOSCRIP,
INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-11993
|
|
05-0489664
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(Employer Identification Number)
|
|
1600 Broadway, Suite 700, Denver, Colorado
80202
(Address of principal executive offices)
(720) 697-5200
(Registrant's telephone number, including
area code)
Not applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
|
|
Emerging growth company
|
|
¨
|
|
|
|
|
|
|
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
|
¨
|
Item 5.02 Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 29, 2018, Alex Schott provided notice
to BioScrip, Inc. that he will be stepping down as Senior Vice President, Strategic Operations and interim Chief Accounting Officer
of BioScrip, Inc. to become Chief Financial Officer of a healthcare company not in the infusion services field. Mr. Schott is expected
to remain in his position at least until June 30, 2018 to assist with the transition of his duties.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
BIOSCRIP, INC.
|
|
|
|
Date:
May 29, 2018
|
|
|
|
By:
|
/s/ Kathryn M. Stalmack
|
|
|
Kathryn M. Stalmack
|
|
|
Senior Vice President, General Counsel and Secretary
|
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Apr 2023 to Apr 2024